GC Pharma

Keyword Search
Plasma Derivatives Office Vaccines Subsidiary Pipeline R&D Media Stock Company Recruit
Product Search
Total Menu KOR

R&DR&D Hightlights


17 Mar, 2017

IV Globulin is a leading plasma-derived product from Green Cross, which has been serving Korean, South American, and other markets worldwide since 1982 to treat a host of diseases related to immunity and infection, including autoimmune diseases, severe infections, and complications of bone marrow transplantation. A Phase-3 clinical trial on IV Globulin in North America has proven its superior efficacy, safety, and tolerance, making Green Cross the first Korean pharmaceutical company to apply for approval from the U.S. Food and Drug Administration (FDA) in 2015.

The global plasma-derived product market has been growing rapidly at an average rate of 11 percent a year over the past decade, amounting to USD 22 billion in value today. The U.S. is by far the largest single-nation market, accounting for USD 3.8 billion. The American Academy of Neurology has recently announced that immunoglobulin drugs have a mitigating effect on the symptoms of Alzheimer’s disease, thereby raising hopes for further growth of this market.